Business Description
Anthem Biosciences Ltd
ISIN : INE0CZ201020
Compare
Compare
Traded in other countries / regions
ANTHEM.India Index Membership
NIFTY 500 IPO Date
2025-07-21Description
Anthem Biosciences Ltd is mainly engaged in discovering, developing, manufacturing, and commercializing biopharmaceutical products that address unmet needs and provide biological solutions to improve industrial performance in all areas. The company offers its CRDMO services to biotech, pharmaceutical, and other companies for the development of large and small drug molecules, and also runs a products business offering specialty ingredients like fermentation products, peptides, lipids, probiotics, APIs, biosimilars, etc. Its reportable segments are: Contract Research Development and Manufacturing Services (CRDMO), which derives maximum revenue, and Specialty Ingredients. Geographically, the company generates maximum revenue from Europe, followed by North America, India, and other regions.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 17.4 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.06 | |||||
Interest Coverage | 106.2 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 70.73 | |||||
Beneish M-Score | -2.39 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 25.8 | |||||
3-Year EBITDA Growth Rate | 18.8 | |||||
3-Year EPS without NRI Growth Rate | 21.6 | |||||
3-Year FCF Growth Rate | 77.9 | |||||
3-Year Book Growth Rate | 20.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.01 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.09 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.51 | |||||
9-Day RSI | 57.21 | |||||
14-Day RSI | 54.97 | |||||
3-1 Month Momentum % | 0.91 | |||||
6-1 Month Momentum % | 26.34 | |||||
12-1 Month Momentum % | 4.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.54 | |||||
Quick Ratio | 5.15 | |||||
Cash Ratio | 2.88 | |||||
Days Inventory | 108.81 | |||||
Days Sales Outstanding | 98.33 | |||||
Days Payable | 45.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.26 | |||||
Dividend Payout Ratio | 0.19 | |||||
Forward Dividend Yield % | 0.26 | |||||
5-Year Yield-on-Cost % | 0.25 | |||||
Shareholder Yield % | 0.35 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.66 | |||||
Operating Margin % | 32.73 | |||||
Net Margin % | 28.76 | |||||
EBITDA Margin % | 46.26 | |||||
FCF Margin % | 31.63 | |||||
OCF Margin % | 42.17 | |||||
ROE % | 21.06 | |||||
ROA % | 18.15 | |||||
ROIC % | 21.93 | |||||
3-Year ROIIC % | 16.87 | |||||
ROC (Joel Greenblatt) % | 46.51 | |||||
ROCE % | 28.15 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 76.74 | |||||
Forward PE Ratio | 60.35 | |||||
PE Ratio without NRI | 74.49 | |||||
Price-to-Owner-Earnings | 58.33 | |||||
PS Ratio | 22.07 | |||||
PB Ratio | 14.38 | |||||
Price-to-Tangible-Book | 14.38 | |||||
Price-to-Free-Cash-Flow | 69.78 | |||||
Price-to-Operating-Cash-Flow | 52.33 | |||||
EV-to-EBIT | 54.35 | |||||
EV-to-EBITDA | 46.28 | |||||
EV-to-Revenue | 21.41 | |||||
EV-to-FCF | 67.69 | |||||
Price-to-Graham-Number | 6.8 | |||||
| Price-to-Net-Current-Asset-Value | 30.88 | |||||
| Price-to-Net-Cash | 79.32 | |||||
Earnings Yield (Greenblatt) % | 1.84 | |||||
FCF Yield % | 1.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anthem Biosciences Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 20,023.41 | ||
| EPS (TTM) (₹) | 10.15 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 54.97 | ||
| 14-Day ATR (₹) | 21.846221 | ||
| 20-Day SMA (₹) | 765.875 | ||
| 12-1 Month Momentum % | 4.59 | ||
| 52-Week Range (₹) | 579.15 - 873.5 | ||
| Shares Outstanding (Mil) | 561.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anthem Biosciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anthem Biosciences Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 2.000000 Cash Dividend | 2026-06-25 | 769.10 (-1.27%) |
Show
Entries
Anthem Biosciences Ltd Frequently Asked Questions
What is Anthem Biosciences Ltd(NSE:ANTHEM)'s stock price today?
The current price of NSE:ANTHEM is ₹778.90. The 52 week high of NSE:ANTHEM is ₹873.50 and 52 week low is ₹579.15.
When is next earnings date of Anthem Biosciences Ltd(NSE:ANTHEM)?
The next earnings date of Anthem Biosciences Ltd(NSE:ANTHEM) is .
Does Anthem Biosciences Ltd(NSE:ANTHEM) pay dividends? If so, how much?
The Dividend Yield %  of Anthem Biosciences Ltd(NSE:ANTHEM) is 0.26% (As of Today), Highest Dividend Payout Ratio of Anthem Biosciences Ltd(NSE:ANTHEM) was 0.19. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Anthem Biosciences Ltd(NSE:ANTHEM) is 0.26%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Anthem Biosciences Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers